Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00973765 · ClinicalTrials.gov registry record · Phase 3

Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses

A Phase 3 study of Abscesses, sponsored by 59th Medical Wing.

Completed
Registry status
Phase 3
Development phase
212
Enrollment target
1
Study location

NCT00973765 is a Phase 3 study of Abscesses that has completed, run by 59th Medical Wing. The registered enrollment target is 212 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00973765, a Phase 3 study of Abscesses, has completed, sponsored by 59th Medical Wing.

COMPLETED
Registry status
Phase 3
Development phase
212 participants
Enrollment target
1
Study location

Study Summary

Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1) placebo two tablets PO BID X 7 days or 2) bactrim DS (800/160) two tablets PO BID x 7 days. Patients will then return to the emergency department ED) at 48 hours and 7 for wound repacking and evaluation. The primary outcome is treatment failure rates at 7 days after incision and drainage. Patients who are clinically worsening or not improving after 48 hours will then be treated with additional antibiotics or admission if needed. Data will be analyzed both by initial randomization and intention to treat.

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG bactrim

Study Locations (1)

Texas

  • Wilford Hall Medical Center - Lackland Air Force Base

Trial Details

FieldValue
Enrollment Target 212 participants
Start Date 2007-11
Est. Completion 2009-08
Phase Phase 3

Sponsor

59th Medical Wing

20 total trials

What the Registry Record Tells You About NCT00973765

The ClinicalTrials.gov registry entry for NCT00973765 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is 59th Medical Wing, which has 20 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Abscesses appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT00973765 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT00973765 about?

NCT00973765 is a clinical study titled "Prospective Randomized Trial of Bactrim on 7 Day Outcome in Patients With Uncomplicated Abscesses". Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1) placebo two tablets PO BID X 7 days or 2) bactrim DS (800/...

What is the current status of trial NCT00973765?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 2007-11. Estimated completion is 2009-08.

What conditions does trial NCT00973765 study?

This clinical trial studies the following conditions: Abscesses.

What interventions are being tested in trial NCT00973765?

The interventions under investigation include: placebo (DRUG), bactrim (DRUG).

Who is sponsoring clinical trial NCT00973765?

This trial is sponsored by 59th Medical Wing, which has 20 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00973765 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.